Literature DB >> 17389465

Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor alpha polymorphic variants.

M Alevizaki1, K Saltiki, A Cimponeriu, I Kanakakis, N Xita, C C Alevizaki, I Georgiou, H-L Sarika.   

Abstract

OBJECTIVE: Impaired estrogen action is a risk factor for coronary artery disease (CAD). Associations of CAD with estrogen receptor alpha (ER alpha) polymorphisms, which may influence sensitivity to estrogen, have been reported for men; the data concerning women are not conclusive. We investigated the association of common ER alpha polymorphisms with the severity of CAD and with metabolic and reproductive factors in postmenopausal women undergoing coronary angiography.
METHODS: ER alpha polymorphisms at positions c.454-397 T>C (PvuII) and c.454-351 A>G (XbaI) were studied in 157 women (age 45-88 years). The severity of CAD was assessed by the number of arteries with >50% stenosis in the angiography.
RESULTS: There was a significant association between the TT, TC, and CC genotypes (PvuII) and the severity of CAD (P=0.008); similar results were obtained for the XbaI polymorphism (P=0.021). These associations were independent of other risk factors for CAD. Women homozygous for the C allele had significantly higher triglyceride and insulin levels; they belonged more frequently to the group with a low number of births (n</=1; P=0.014, Fisher's exact).
CONCLUSIONS: Common ER alpha polymorphisms may influence the severity of CAD in women undergoing coronary angiography, reflecting lifetime exposure to estrogen. Similar associations have been reported for men with CAD. These polymorphisms should probably be taken into account when associations with estrogenic actions are examined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389465     DOI: 10.1530/EJE-06-0685

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  20 in total

1.  In silico characterization of functional SNP within the oestrogen receptor gene.

Authors:  Maha Rebaï; Ahmed Rebaï
Journal:  J Genet       Date:  2016-12       Impact factor: 1.166

Review 2.  Potential approaches to enhance the effects of estrogen on senescent blood vessels and postmenopausal cardiovascular disease.

Authors:  Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-01

Review 3.  Vascular effects of estrogenic menopausal hormone therapy.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Rev Recent Clin Trials       Date:  2012-02

4.  No Association of Genetic Markers with Carotid Intimal Medial Thickness in β-Thalassemia Major Patients.

Authors:  Mable Misha Singh; Ravindra Kumar; Satyendra Tewari; Sarita Agarwal
Journal:  J Pediatr Genet       Date:  2017-12-06

Review 5.  Sex Hormones and Cardiometabolic Health: Role of Estrogen and Estrogen Receptors.

Authors:  Deborah Clegg; Andrea L Hevener; Kerrie L Moreau; Eugenia Morselli; Alfredo Criollo; Rachael E Van Pelt; Victoria J Vieira-Potter
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

6.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

Review 7.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 8.  Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.

Authors:  Joanne Ryan; Marie-Laure Ancelin
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

9.  Genetic determinants of osteoporosis: common bases to cardiovascular diseases?

Authors:  Francesca Marini; Maria Luisa Brandi
Journal:  Int J Hypertens       Date:  2010-03-25       Impact factor: 2.420

10.  ESR1 polymorphisms and statin therapy: a sex-specific approach.

Authors:  L Smiderle; M Fiegenbaum; M H Hutz; C R Van Der Sand; L C Van Der Sand; M E W Ferreira; R C Pires; S Almeida
Journal:  Pharmacogenomics J       Date:  2015-08-25       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.